Keye Life Sciences

Keye Life Sciences is a clinical-stage biotechnology company and a subsidiary of Roivant Sciences, focused on developing novel therapies for metabolic and inflammatory diseases. The company's lead program, KYE-1001, is a potent and selective GPR119 agonist designed to improve glycemic control and promote weight loss in patients with type 2 diabetes and obesity. By targeting GPR119, Keye aims to leverage the receptor's dual role in stimulating insulin secretion and releasing incretin hormones like GLP-1. The company operates within the Roivant "Vant" model, utilizing centralized resources to accelerate the development of its metabolic pipeline. Keye Life Sciences is currently advancing its lead candidate through early-stage clinical trials to establish safety and proof-of-concept.